Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on AdAlta.
RELATED STOCKHEAD STORIES
Stockhead TV
What’s in store for 2024: AdAlta
Experts
Money Talks: Keep an eye on these tasty precious metal and biotech plays in 2024
Stockhead TV
Long Shortz with AdAlta: How the company has potentially broken the malaria life cycle
News
In Case You Missed It: New niobium and REE projects plus scaffold distribution deals
Health & Biotech
‘World first’: AdAlta’s i-body platform a breakthrough for malaria treatment
News
In Case You Missed It: Heavy mineral sands, a biotech takeover and some gold
Health & Biotech
AdAlta on track for trial readout in Q1 2024 after $1.65m cap raise
Health & Biotech
‘Best place we’ve ever been’: AdAlta looks to monetise lead asset in 2024
News
In Case You Missed It: UAE agricultural deliveries and some Swedish lithium
Health & Biotech
AdAlta’s latest results bolster safety profile and dose selection for primary asset, enhancing partnering, reducing Phase 2 trial risks
Health & Biotech
ASX Health Stocks: Painchek’s Europe patent accepted; and HeraMed signs deal with Telstra Health
News
Closing Bell: ASX has best week ever… or at least since everything crashed last month. So… wait… damn you Friday!
News
Market Highlights: Wall Street slips, common mistakes in stock trading, and 5 ASX small caps to watch today
Health & Biotech
ASX Health Stocks: Mesoblast crashes 54pc after FDA says it needs more data for approval
News
Rise and Shine: Everything you need to know before the ASX opens
News
CLOSING BELL: Investors in pain as ASX falls 1.69% to 50-day low
News
